GemciTest®
Pancreatic Cancer (Predicting response to Gemcitabine)
Pre-clinical/ValidationActive
Key Facts
Indication
Pancreatic Cancer (Predicting response to Gemcitabine)
Phase
Pre-clinical/Validation
Status
Active
Company
About Acobiom
Acobiom is a private, innovative biotech firm at the forefront of precision medicine diagnostics. Its core asset is GemciTest®, a blood-based diagnostic test designed to predict pancreatic cancer patient response to gemcitabine chemotherapy, aiming to optimize treatment selection. Beyond this lead program, the company operates a robust omics services business, providing RNA-Seq, qPCR, and bioinformatics analysis to support translational research for external clients. Acobiom's strategy combines service revenue with the high-value development of proprietary diagnostic tests.
View full company profile